Dermatology

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug FB-401 failed to meet a statistical significance, the company said. Topline data from a Phase 2...

Ra Medical Systems Inc (NYSE: RMED) has sold its Pharos dermatology business to STRATA Skin Sciences Inc (NASDAQ: SSKN) for $3.7 million in cash.  The Pharos excimer laser is an FDA-cleared treatment for psoriasis, vitiligo, atopic dermatitis, and leukoderma. "We believe...

Fortress Biotech Inc's (NASDAQ: FBIO) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc, a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY). The transaction is...

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has entered into an agreement with EMC Pharma LLC for the exclusive right to manage, market, and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the U.S. for an initial term of five years, subject to...

Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA) at its June 15 IPO are celebrating 13.1-percent returns. The gains should continue, in the view of two new sell-side bulls. The Ratings Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Verrica with a Buy...

Strata Skin Sciences, Inc. (NASDAQ: SSKN), a nano-cap medical technology company that develops, commercializes and markets innovative products for the treatment of dermatologic conditions, has a more than 400 percent upside, according to HC Wainwright & Co's Joseph Pantginis. Pantginis...